Co-Diagnostics

Co-Diagnostics, Inc. engages in the development and innovation of molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. Its diagnostics systems enable very rapid, low-cost, molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests. The company was founded by Brent C. Satterfield and Dwight Howard Egan on April 18, 2013 and is headquartered in Salt Lake City, UT.

Earnings data Q4 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Full-year Results Impacted by Lower Demand for COVID-19 Testing Announced Initiation of Clinical Evaluations for Co-Dx PCR Home™ Platform SALT LAKE CITY , March 16, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today financial results for the full year ended December 31, 2022. Full Year 2022 Financial Results: Revenue of $34.2 million, down from $97.9 million during the prior year primarily due to lower global demand for the Logix Smart™ COVID-19 tests Gross profit of $28.7 million, representing 84.0% of consolidated revenu Operating loss of $27.0 million compared to operating income of $46.1 million a year ago, due to lower revenue, goodwill impairment charges, and continued investments into research and development for the Co-Dx PCR Home Platform Net loss of $14.2 million, compared to net income of $36.7 million in the prior year, representing loss of $0.45 per fully diluted share, compared to $1.23 in 2021 Adjusted net income, net of goodwill impairment charges, of $1.2 million, compared to adjusted net income of $36.7 million in the prior year, representing adjusted income of $0.04 per fully diluted share, compared to $1.23 in 2021 Adjusted EBITDA loss of $3.1 million Repurchased 3.9 million shares of common stock at an average price of $3.66 per share for an aggregate purchase price of approximately $14.2 million Cash, cash equivalents, and marketable securities of $81.3 million as of December 31, 2022 Cash flow from operations of $6.6 million for the twelve months ended December 31, 2022 Dwight Egan, Co-Diagnostics' Chief Executive Officer, said, "The impact of COVID-19 on society decreased considerably during the second half of the year, and resulted in lower demand for high-throughput testing at the centralized lab level.

Co-Diagnostics, Inc. Reports Full Year 2022 Financial Results

SALT LAKE CITY , March 9, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its fourth quarter and full year 2022 results on Thursday, March 16, 2023, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m.

CO-DIAGNOSTICS, INC. ANNOUNCES FOURTH QUARTER AND FULL YEAR 2022 EARNINGS RELEASE DATE AND WEBCAST

SALT LAKE CITY , March 2, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be hosting a booth at the 30th Molecular and Precision Med TRI-CON ("TRI-CON"), held virtually and in person March 6-8, 2023, in San Diego, CA. Co-Dx, which is also one of two Premier Sponsors of the event, will also be delivering the Lunch Presentation on Monday, March 6 at 11:55 am, focusing on its upcoming at-home/POCT Co-Dx PCR Home™ platform for which the initiation of clinical evaluations was recently announced.

Co-Diagnostics, Inc. to Present and Host Booth at TRI-CON in San Diego, CA, March 6-8

SALT LAKE CITY , Feb. 28, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be hosting a booth at the upcoming 89th annual American Mosquito Control Association (AMCA) conference on February 28-March 3 in Reno, Nevada. The AMCA Annual Meeting is listed as the premier education and networking event for researchers, educators, vector control professionals, industry representatives, and students in mosquito control.

Co-Diagnostics, Inc. to Host Booth at 89th Annual AMCA Conference in Reno, NV on Feb 28-March 3

SALT LAKE CITY , Feb. 22, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it has commenced clinical evaluations for its at-home and point-of-care Co-Dx PCR Home™ platform and initial COVID-19 test, consisting of the clinical trials and analytical studies that are expected to support submissions to the United States FDA and other regulatory bodies. The Company's real-time PCR platform has been developed for detection of infectious diseases in at-home and point-of-care settings, with anticipated multiplex panels to follow after receipt of the platform's initial regulatory authorization.

Co-Diagnostics, Inc. Initiates Clinical Evaluations for its At-Home and Point-of-Care Co-Dx PCR Home™ Platform

Wilmington, Delaware--(Newsfile Corp. - February 7, 2023) - Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of Co-Diagnostics, Inc. (NASDAQ: CODX) on behalf of stockholders.To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-co-diagnostics-inc.To contact Seth D. Rigrodsky or Gina M. Serra cost free, call or text (302) 295-5310 or email info@rl-legal.com.Rigrodsky Law, P.A.

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Co-Diagnostics, Inc.

SALT LAKE CITY , Feb. 2, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be hosting a booth at the upcoming Medlab Middle East 2023 trade show held February 6-9 at the Dubai World Trade Centre. It is expected that the 22nd edition of the conference will host over 20,000 visitors and more than 700 exhibitors from over 40 countries, catering to the global medical laboratory community and showcasing the latest in laboratory innovation and technology.

Co-Diagnostics, Inc. to Host Booth at Medlab Middle East 2023 in Dubai on February 6-9

Designed using the Company's proprietary platform, initial test design remains effective detection tool even after three years of variants and more than 33 million sold worldwide; Company also announces participation in Life Sciences Day on the Hill on Jan 27 SALT LAKE CITY , Jan. 24, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, yesterday commemorated the third anniversary of the completion of the principal design work of a Co-Primers™ PCR test for what was, on January 23, 2020, still known as 2019-nCoV, or the novel coronavirus. The initial design was rapidly completed using the Company's proprietary Co-Dx™ Design platform.

Co-Diagnostics, Inc. Commemorates Third Anniversary of the Completion of its First COVID-19 Test Design

SALT LAKE CITY , Nov. 30, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Co-Diagnostics will be presenting on December 1, 2022, at the Piper Sandler 34th Annual Healthcare Conference, held November 29-December 31, 2022, in New York City, New York. Dwight Egan, Company CEO, and Dr. Kirk Ririe, President of the Company's subsidiary, will be conducting a presentation discussing recent and expected Company progress along with its forthcoming Co-Dx PCR diagnostic platform.

Co-Diagnostics, Inc. to Present at the Piper Sandler 34th Annual Healthcare Conference on December 1, 2022

SALT LAKE CITY , Nov. 14, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be hosting a booth this week at the MEDICA 2022 trade fair in Düsseldorf, Germany from 15-17 November. After more than 40 years, MEDICA has become the largest medical trade fair in the world, attracting thousands of exhibitors from more than 50 countries.

Co-Diagnostics, Inc. to Host Booth at MEDICA 2022 Trade Fair in Düsseldorf, Germany

Co-Diagnostics Inc (NASDAQ:CODX) posted financial results for the third quarter that revealed ample cash on hand, giving the company scope to further advance its Co-Dx PCR Home testing platform for infectious diseases.   As of September 30, 2022, the Salt Lake City, Utah-based molecular diagnostics company, had cash, equivalents, and marketable securities of $86.5 million.

Co-Diagnostics ends 3Q with $86.5M in cash; makes significant progress on its Co-Dx PCR Home platform

Co-Diagnostics, Inc. (NASDAQ:CODX ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Dan Bohrer - VP, Finance and Accounting Dwight Egan - CEO Brian Brown - CFO Conference Call Participants Theodore O'Neill - Litchfield Hills Research Operator Good afternoon, and welcome to the Co-Diagnostics, Inc. Third Quarter 2022 Earnings Results Conference Call. [Operator Instructions] Please note, this event is being recorded.

Co-Diagnostics, Inc. (CODX) Q3 2022 Earnings Call Transcript

CoDiagnostics, Inc. (CODX) delivered earnings and revenue surprises of 33.33% and 24.53%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

CoDiagnostics, Inc. (CODX) Reports Q3 Loss, Lags Revenue Estimates

Nearing commencement of clinical evaluations for the Co-Dx PCR Home platform COVID-19 test volumes continue to impact third quarter results SALT LAKE CITY , Nov. 10, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today financial results for the third quarter ended September 30, 2022. Third Quarter 2022 Financial Results: Revenue of $5.1 million, down from $30.1 million during the prior year period, but an increase of 1.4% from the current year second quarter Gross profit of $4.3 million, representing 84.9% of consolidated revenue Operating loss of $6.5 million compared to operating income of $13.6 million a year ago, due to lower sales volumes and continued investments into research and development for the Co-Dx PCR Home Platform Net loss of $1.4 million, compared to a net income of $11.5 million in the prior-year third quarter, representing a loss of $0.04 per fully diluted share Adjusted EBITDA loss of $4.1 million Repurchased 2.9 million shares during the third quarter at an average price of $3.61 per share Cash, cash equivalents, and marketable securities of $86.5 million as of September 30, 2022 Cash flow from operations of $10.6 million for the nine months ended September 30, 2022, of which $1.1 million was generated in the third quarter Dwight Egan, Co-Diagnostics' Chief Executive Officer, remarked, "While our third quarter results were impacted by lower demand for our COVID-19 test, we made significant progress on our Co-Dx PCR Home™ platform which is nearing its final stages.

Co-Diagnostics, Inc. Reports Third Quarter 2022 Financial Results

SALT LAKE CITY , Nov. 3, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that the Company is hosting a booth this week at the Association for Molecular Pathology ("AMP") annual expo, held November 1-5 in Phoenix, AZ. The conference website describes AMP as the leading organization in the field of molecular diagnostics, with their annual meeting being considered the "premier gathering" of molecular professionals to explore how cutting-edge technology and developments in molecular testing and diagnostics continue to have a major impact on patient care.

Co-Diagnostics, Inc. to Host Booth at AMP This Week in Phoenix, AZ

Co-Diagnostics Inc (NASDAQ:CODX) has announced the appointment of Mark Poritz as the company's new chief scientific officer (CSO). Poritz is a Harvard University-educated molecular biologist with more than 30 years of experience in the application of polymerase chain reaction (PCR) and related methods to gene cloning, drug discovery, infectious disease diagnostics and aptamer selection.

Co-Diagnostics appoints veteran molecular biologist Mark Poritz as its new chief scientific officer

SALT LAKE CITY , Nov. 1, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx™" or the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it is pleased to welcome Mark Poritz, PhD as the Company's new Chief Scientific Officer ("CSO"). Dr. Poritz is a Harvard University and UC San Francisco educated molecular biologist with more than 30 years of experience in the application of PCR and related methods to gene cloning, drug discovery, infectious disease diagnostics and aptamer selection, who has also served as a reviewer for more than 30 different NIH/NIAID study sections focusing on infectious disease diagnostics.

Co-Diagnostics, Inc. Appoints Dr. Mark Poritz as New Chief Scientific Officer

SALT LAKE CITY , Oct. 27, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its third quarter 2022 results on Thursday, November 10, 2022, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m.

CO-DIAGNOSTICS, INC. ANNOUNCES THIRD QUARTER 2022 EARNINGS RELEASE DATE AND WEBCAST

SALT LAKE CITY , Oct. 26, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that the Company will be hosting a booth this week at Africa Health/Medlab Africa in Johannesburg, South Africa on October 26-28, 2022. The conference is the largest gathering of healthcare companies, technology, products and services in the sub-Saharan region, catering to an audience of professionals from the South African Development Community region and around the world, including distributors, government representatives, laboratory executives, and purchasing/procurement managers, who attend to meet with world-class suppliers and manufacturers.

Co-Diagnostics, Inc. to Host Booth at Medlab Africa on Oct 26-28 in South Africa

SALT LAKE CITY , Oct. 19, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that the Company will be hosting booths this week at IDWeek 2022 in Washington, D.C., and at Asia Health/Medlab Asia in Bangkok, Thailand.

Co-Diagnostics, Inc. to Host Booths at Conferences in Washington, D.C. and Bangkok, Thailand

NEW YORK , Oct. 19, 2022 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Co-Diagnostics, Inc.. Shareholders who purchased shares of CODX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Co-Diagnostics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 17, 2022 - (NASDAQ: CODX)

San Francisco, California--(Newsfile Corp. - October 17, 2022) - Hagens Berman urges Co-Diagnostics, Inc. (NASDAQ: CODX) investors who suffered significant losses to submit your losses now. Class Period: May 12, 2022 - Aug. 11, 2022Lead Plaintiff Deadline: Oct. 17, 2022Visit: www.hbsslaw.com/investor-fraud/CODXContact An Attorney Now: CODX@hbsslaw.com844-916-0895Co-Diagnostics, Inc. (NASDAQ: CODX) Securities Fraud Class Action: Throughout the Class Period, Defendants repeatedly touted Co-Diagnostics' Logix Smart COVID-19 Test and, as

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Co-Diagnostics (CODX) Investors of Today's Lead Plaintiff Deadline in Securities Class Action

Los Angeles, California--(Newsfile Corp. - October 17, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Co-Diagnostics, Inc. ("Co-Diagnostics" or "the Company") (NASDAQ: CODX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

DEADLINE TODAY: The Schall Law Firm Encourages Investors in Co-Diagnostics, Inc. with Losses of $100,000 to Contact the Firm

New York, New York--(Newsfile Corp. - October 16, 2022) - Levi & Korsinsky, LLP notifies investors in Co-Diagnostics, Inc. ("Co-Dx" or the "Company") (NASDAQ: CODX) of a class action securities lawsuit.The lawsuit on behalf of Co-Dx investors has been commenced in the the United States District Court for the Southern District of New York.

Co-Dx Class Action: Levi & Korsinsky Reminds Co-Diagnostics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 17, 2022 - CODX

New York, New York--(Newsfile Corp. - October 16, 2022) - Pomerantz LLP announces that a class action lawsuit has been filed against Co-Diagnostics, Inc. (NASDAQ: CODX) ("Co-Dx" or the "Company") and certain of its officers.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Co-Diagnostics, Inc. of Class Action Lawsuit and Upcoming Deadline - CODX

News for Co-Diagnostics Stock (CODX)